Biotie receives positive opinion on orphan drug status for BTT1023 from EMA
Finnish biotech and pharma company Biotie has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products, recommending orphan drug designation for BTT1023 in primary sclerosing cholangitis.
This is a chronic, progressive fibrotic liver disease for which there are currently no effective treatments.
BTT1023 is a fully human monoclonal antibody that targets vascular adhesion protein -1, and is currently advancing into Phase II clinical development. The BUTEO study will be an open label, single arm, multicenter investigator-sponsored study that will be conducted in partnership with the University of Birmingham, UK and supported through external grant funding.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze